Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Hanover Medical Specialts PA
mi
from
Wilmington, NC
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hanover Medical Specialts PA
mi
from
Wilmington, NC
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Gabrail Cancer Center
mi
from
Canton, OH
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University Hospitals of Cleveland
mi
from
Cleveland, OH
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Providence Portland Medical Center
mi
from
Portland, OR
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Center for Oncology Research
mi
from
Dallas, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Center for Oncology Research
mi
from
Dallas, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Cancer Therapy & Research Center, Institute for Drug Development
mi
from
San Antonio, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Therapy & Research Center, Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Fairfax-Northern Virginia Hematology Oncology, PC
mi
from
Fairfax, VA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Fairfax-Northern Virginia Hematology Oncology, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Wheeling Hospital
mi
from
Wheeling, WV
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Wheeling Hospital
mi
from
Wheeling, WV
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
Hospital Italiano Regional del Sur
mi
from
Bahia Blanca,
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hospital Italiano Regional del Sur
mi
from
Bahia Blanca,
Click here to add this to my saved trials
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated:  10/19/2015
Southern Arizona VA Medical Center
mi
from
Tucson, AZ
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated: 10/19/2015
Southern Arizona VA Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated:  10/19/2015
Bethesda Naval Medical Center
mi
from
Bethesda, MD
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated: 10/19/2015
Bethesda Naval Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated:  10/19/2015
Department of Veterans Affairs Medical Center
mi
from
Kansas City, MO
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated: 10/19/2015
Department of Veterans Affairs Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated:  10/19/2015
Cleveland Clinic
mi
from
Cleveland, OH
The Study of Barrett's Esophagus: What Are the Factors of Progression
Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project
Status: Enrolling
Updated: 10/19/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
St. Vincent Hospital & Health Centers
mi
from
Indianapolis, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
St. Vincent Hospital & Health Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Horizon Oncology Researcg
mi
from
Lafayette, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Horizon Oncology Researcg
mi
from
Lafayette, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
IU Health Arnett Cancer Center
mi
from
Lafayette, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
IU Health Arnett Cancer Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
IU Health at Ball Memorial Hospital
mi
from
Muncie, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
IU Health at Ball Memorial Hospital
mi
from
Muncie, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Monroe Medical Associates
mi
from
Munster, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Monroe Medical Associates
mi
from
Munster, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Providence Medical Group
mi
from
Terre Haute, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Providence Medical Group
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Methodist Cancer Center
mi
from
Omaha, NE
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Methodist Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Providence Portland Medical Center
mi
from
Portland, OR
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated:  10/19/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Status: Enrolling
Updated: 10/19/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Click here to add this to my saved trials
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated:  10/19/2015
Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology
mi
from
Pittsburgh, PA
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated: 10/19/2015
Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated:  10/19/2015
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated: 10/19/2015
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated:  10/19/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated: 10/19/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated:  10/19/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Status: Enrolling
Updated: 10/19/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Outlook Quality of Life Intervention Study
Outlook: An Intervention to Improve Quality of Life in Serious Illness Study
Status: Enrolling
Updated:  10/19/2015
Durham VA Medical Center HSR&D COE
mi
from
Durham, NC
Outlook Quality of Life Intervention Study
Outlook: An Intervention to Improve Quality of Life in Serious Illness Study
Status: Enrolling
Updated: 10/19/2015
Durham VA Medical Center HSR&D COE
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical and Translational Study of STA-9090
A Phase II Clinical and Translational Study of STA-9090 in Patients With Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical and Translational Study of STA-9090
A Phase II Clinical and Translational Study of STA-9090 in Patients With Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated:  10/19/2015
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated: 10/19/2015
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials